File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effect of midtreatment PET/CT-adapted radiation therapy with concurrent chemotherapy in patients with locally advanced non–small-cell lung cancer: A phase 2 clinical trial

TitleEffect of midtreatment PET/CT-adapted radiation therapy with concurrent chemotherapy in patients with locally advanced non–small-cell lung cancer: A phase 2 clinical trial
Authors
Issue Date2017
Citation
JAMA Oncology, 2017, v. 3, n. 10, p. 1358-1365 How to Cite?
Abstract© 2017 American Medical Association. All rights reserved. IMPORTANCE: Our previous studies demonstrated that tumors significantly decrease in size and metabolic activity after delivery of 45 Gy of fractionated radiatiotherapy (RT), and that metabolic shrinkage is greater than anatomic shrinkage. This study aimed to determine whether 18F-fludeoxyglucose–positron emission tomography/computed tomography (FDG-PET/CT) acquired during the course of treatment provides an opportunity to deliver higher-dose radiation to the more aggressive areas of the tumor to improve local tumor control without increasing RT-induced lung toxicity (RILT), and possibly improve survival. OBJECTIVE: To determine whether adaptive RT can target high-dose radiation to the FDG-avid tumor on midtreatment FDG-PET to improve local tumor control of locally advanced non–small-cell lung cancer (NSCLC). DESIGN, SETTING, AND PARTICIPANTS: A phase 2 clinical trial conducted at 2 academic medical centers with 42 patients who had inoperable or unresectable stage II to stage III NSCLC enrolled from November 2008, to May 2012. Patients with poor performance, more than 10% weight loss, poor lung function, and/or oxygen dependence were included, providing that the patients could tolerate the procedures of PET scanning and RT. INTERVENTION: Conformal RT was individualized to a fixed risk of RILT (grade >2) and adaptively escalated to the residual tumor defined on midtreatment FDG-PET up to a total dose of 86 Gy in 30 daily fractions. Medically fit patients received concurrent weekly carboplatin plus paclitaxel followed by 3 cycles of consolidation. MAIN OUTCOMES AND MEASURES: The primary end point was local tumor control. The trial was designed to achieve a 20% improvement in 2-year control from 34% of our prior clinical trial experience with 63 to 69 Gy in a similar patient population. RESULTS: The trial reached its accrual goal of 42 patients: median age, 63 years (range, 45-83 years); male, 28 (67%); smoker or former smoker, 39 (93%); stage III, 38 (90%). Median tumor dose delivered was 83 Gy (range, 63-86 Gy) in 30 daily fractions. Median follow-up for surviving patients was 47 months. The 2-year rates of infield and overall local regional tumor controls (ie, including isolated nodal failure) were 82% (95% CI, 62%-92%) and 62% (95% CI, 43%-77%), respectively. Median overall survival was 25 months (95% CI, 12-32 months). The 2-year and 5-year overall survival rates were 52% (95% CI, 36%-66%) and 30% (95% CI, 16%-45%), respectively. CONCLUSIONS AND RELEVANCE: Adapting RT-escalated radiation dose to the FDG-avid tumor detected by midtreatment PET provided a favorable local-regional tumor control. The RTOG 1106 trial is an ongoing clinical trial to validate this finding in a randomized fashion. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01190527.
Persistent Identifierhttp://hdl.handle.net/10722/267076
ISSN
2017 Impact Factor: 20.871
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorKong, Feng Ming-
dc.contributor.authorTen Haken, Randall K.-
dc.contributor.authorSchipper, Matthew-
dc.contributor.authorFrey, Kirk A.-
dc.contributor.authorHayman, James-
dc.contributor.authorGross, Milton-
dc.contributor.authorRamnath, Nithya-
dc.contributor.authorHassan, Khaled A.-
dc.contributor.authorMatuszak, Martha-
dc.contributor.authorRitter, Timothy-
dc.contributor.authorBi, Nan-
dc.contributor.authorWang, Weili-
dc.contributor.authorOrringer, Mark-
dc.contributor.authorCease, Kemp B.-
dc.contributor.authorLawrence, Theodore S.-
dc.contributor.authorKalemkerian, Gregory P.-
dc.date.accessioned2019-01-31T07:20:26Z-
dc.date.available2019-01-31T07:20:26Z-
dc.date.issued2017-
dc.identifier.citationJAMA Oncology, 2017, v. 3, n. 10, p. 1358-1365-
dc.identifier.issn2374-2437-
dc.identifier.urihttp://hdl.handle.net/10722/267076-
dc.description.abstract© 2017 American Medical Association. All rights reserved. IMPORTANCE: Our previous studies demonstrated that tumors significantly decrease in size and metabolic activity after delivery of 45 Gy of fractionated radiatiotherapy (RT), and that metabolic shrinkage is greater than anatomic shrinkage. This study aimed to determine whether 18F-fludeoxyglucose–positron emission tomography/computed tomography (FDG-PET/CT) acquired during the course of treatment provides an opportunity to deliver higher-dose radiation to the more aggressive areas of the tumor to improve local tumor control without increasing RT-induced lung toxicity (RILT), and possibly improve survival. OBJECTIVE: To determine whether adaptive RT can target high-dose radiation to the FDG-avid tumor on midtreatment FDG-PET to improve local tumor control of locally advanced non–small-cell lung cancer (NSCLC). DESIGN, SETTING, AND PARTICIPANTS: A phase 2 clinical trial conducted at 2 academic medical centers with 42 patients who had inoperable or unresectable stage II to stage III NSCLC enrolled from November 2008, to May 2012. Patients with poor performance, more than 10% weight loss, poor lung function, and/or oxygen dependence were included, providing that the patients could tolerate the procedures of PET scanning and RT. INTERVENTION: Conformal RT was individualized to a fixed risk of RILT (grade >2) and adaptively escalated to the residual tumor defined on midtreatment FDG-PET up to a total dose of 86 Gy in 30 daily fractions. Medically fit patients received concurrent weekly carboplatin plus paclitaxel followed by 3 cycles of consolidation. MAIN OUTCOMES AND MEASURES: The primary end point was local tumor control. The trial was designed to achieve a 20% improvement in 2-year control from 34% of our prior clinical trial experience with 63 to 69 Gy in a similar patient population. RESULTS: The trial reached its accrual goal of 42 patients: median age, 63 years (range, 45-83 years); male, 28 (67%); smoker or former smoker, 39 (93%); stage III, 38 (90%). Median tumor dose delivered was 83 Gy (range, 63-86 Gy) in 30 daily fractions. Median follow-up for surviving patients was 47 months. The 2-year rates of infield and overall local regional tumor controls (ie, including isolated nodal failure) were 82% (95% CI, 62%-92%) and 62% (95% CI, 43%-77%), respectively. Median overall survival was 25 months (95% CI, 12-32 months). The 2-year and 5-year overall survival rates were 52% (95% CI, 36%-66%) and 30% (95% CI, 16%-45%), respectively. CONCLUSIONS AND RELEVANCE: Adapting RT-escalated radiation dose to the FDG-avid tumor detected by midtreatment PET provided a favorable local-regional tumor control. The RTOG 1106 trial is an ongoing clinical trial to validate this finding in a randomized fashion. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01190527.-
dc.languageeng-
dc.relation.ispartofJAMA Oncology-
dc.titleEffect of midtreatment PET/CT-adapted radiation therapy with concurrent chemotherapy in patients with locally advanced non–small-cell lung cancer: A phase 2 clinical trial-
dc.typeArticle-
dc.description.natureLink_to_OA_fulltext-
dc.identifier.doi10.1001/jamaoncol.2017.0982-
dc.identifier.pmid28570742-
dc.identifier.scopuseid_2-s2.0-85028912482-
dc.identifier.volume3-
dc.identifier.issue10-
dc.identifier.spage1358-
dc.identifier.epage1365-
dc.identifier.eissn2374-2445-
dc.identifier.isiWOS:000412879700017-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats